Investors Are Bullish on Exact Sciences - Here's What You Need to Know.

By Harris Dyer • Saturday, December 02 14:15 • Permanent Link

This afternoon we watched Exact Sciences rise 4.7% to a price of $67.03 per share. The mid-cap None company is now trading -27.68% below its average target price of $92.69. Analysts have set target prices ranging from $66.0 to $120.0 per share for Exact Sciences, and have given the stock an average rating of buy.

The stock has None at 4.1%, and a short ratio of 4.71. The company's insiders own 0.93% of its outstanding shares, which indicates a strong alignment between management and shareholder interests. Finally, we also note that None are invested in the stock, with 88.8% of Exact Sciences's shares being owned by this investor type.

Institutions Invested in Exact Sciences

Date Reported	Holder	Percentage	Shares	Value
2023-09-30	JP Morgan Chase & Company	10%	18,292,619	$1,226,154,229
2023-09-30	Vanguard Group Inc	10%	17,444,693	$1,169,317,750
2023-09-30	Blackrock Inc.	6%	11,575,558	$775,909,638
2023-09-30	Wellington Management Group, LLP	6%	10,820,873	$725,323,103
2023-09-30	Capital World Investors	4%	6,928,647	$464,427,199
2023-09-30	ARK Investment Management, LLC	3%	6,280,931	$421,010,797
2023-09-30	State Street Corporation	2%	4,510,603	$302,345,713
2023-09-30	Baillie Gifford and Company	2%	4,066,330	$272,566,094
2023-09-30	Artisan Partners Limited Partnership	2%	3,961,514	$265,540,278
2023-09-30	Ameriprise Financial, Inc.	2%	3,239,648	$217,153,601

Besides None, other market factors point to there being None on Exact Sciences.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.